PET/CT GUIDED BIOPSY VERSUS CT GUIDED BIOPSY IN EVALUATION OF SUSPECTED LUNG NEOPLASMS
Launched by ALL INDIA INSTITUTE OF MEDICAL SCIENCES, BHUBANESWAR · Apr 4, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is comparing two different methods for obtaining tissue samples from suspected lung tumors: PET/CT guided biopsy and traditional CT guided biopsy. The researchers want to see which method is better at accurately diagnosing lung cancer and which has fewer complications. PET/CT guided biopsy is thought to be more effective because it can pinpoint the areas with the highest concentration of cancer cells, which may lead to clearer results than the standard method.
To participate in this study, individuals must be at least 18 years old and have a lung lesion larger than 10 millimeters that can be reached for a biopsy. They should also have normal blood clotting levels. However, people with certain bleeding disorders, those who are pregnant or breastfeeding, and those with specific health issues like low oxygen levels or kidney problems cannot participate. If eligible, participants will undergo one of the biopsy methods and will be monitored for any side effects. This trial is currently recruiting participants, and it aims to improve how doctors diagnose lung diseases in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age above 18 years
- • INR \< 1.2 and platelet counts \> 80,000/mm3
- • CT thorax with lung lesion more than 10 mm.
- • Accessible lesions for CT-guided biopsy.
- Exclusion Criteria:
- • Participants with pre-existing bleeding diathesis like hemophilia, coagulopathy defined by -INR ≥1.2 and Platelet counts ≤ 80,000/mm3
- • Participants who refuse to provide consent
- • Signs of hypoperfusion like hypotension, cyanosis etc.
- • Presence of hypoxemia with SpO2 \< 94 %- measured in a pulse oximeter)
- • Pregnant/Lactating female subjects
- • Non-cooperative subjects
- • Lesions that are inaccessible (decision made on pre-biopsy planning)
- • Serum creatinine level more than 2mg/dl.
About All India Institute Of Medical Sciences, Bhubaneswar
The All India Institute of Medical Sciences (AIIMS), Bhubaneswar, is a premier medical research and educational institution dedicated to advancing healthcare through innovative clinical trials and research initiatives. Established to provide high-quality medical education and comprehensive patient care, AIIMS Bhubaneswar focuses on developing cutting-edge treatments and therapies to address pressing health challenges in India and beyond. With a commitment to ethical research practices and collaboration with national and international partners, AIIMS Bhubaneswar plays a pivotal role in enhancing medical knowledge and improving patient outcomes through evidence-based practices.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bhubaneswar, Odisha, India
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported